Status:
UNKNOWN
Copeptin and HFABP in Cardiac Surgery
Lead Sponsor:
Heinrich-Heine University, Duesseldorf
Conditions:
Coronary Artery Disease
Valvular Heart Disease
Eligibility:
All Genders
18+ years
Brief Summary
In-hospital mortality after cardiac surgery ranges from 2-6%. Many patients suffer from major adverse cardiovascular events (MACE) which results in impaired disability-free survival. Troponin plays th...
Detailed Description
The initial patient visit will take place after screening of patients and eligibility assessment and no later than on the day before surgery (day -1). After provision of patient information and writte...
Eligibility Criteria
Inclusion
- Adult (≥ 18 years of age)
- Elective surgery
- On-pump cardiac surgery (CABG and/or valvular surgery)
Exclusion
- Heart transplantation (HTX)
- ACS at presentation (\< 14 days)
- Emergency surgery
- Preoperative inotropic or mechanical circulatory support
- Left or right ventricular assist device implantation
- Unwilling or unable to provide consent
- Inability to follow the procedures of the study, e.g. due to language barriers, psychiatric disorders, dementia
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2023
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04877795
Start Date
April 1 2021
End Date
June 30 2023
Last Update
May 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heinrich-Heine-Universität
Düsseldorf, North Rhine-Westphalia, Germany, 40225